Advertisement

Acute Termination of Atrial Flutter: Are New Class Antiarrhythmic Drugs the Best Choice?

  • N. Baldi
  • V. A. Russo
  • V. Morrone
  • L. Di Gregorio
  • L. Liconso
  • G. Polimeni
Conference paper

Abstract

The expression “atrial flutter” (AFI) covers a series of arrhythmias which are related to different physiopathological mechanisms: typical AFI (common and uncommon, referring respectively to the anti-clockwise and clockwise routes through the anatomical substrate of right atrium, septum-lateral wall and isthmus inferior vena cava-tricuspid) and the atypical AFI, in which the circuit is located differently. In the population the prevalence of AFI is less than one in a thousand. Uncommon AFI is ten times less frequent than common AFI. The atypical form includes a heterogeneous series of arrhythmias whose electroge-netic mechanism is not exhaustively known and in which the absence of an excitable gap makes it very difficult to achieve entrainment or reset through the technique of pacing. Recently Cheng et al. [1] have shown that the site of the atypical flutter circuit is the lower part of the right atrium, while Jais et al. [2] have reported some cases of left AFI. As a consequence of this, we suggest that the arrhythmias generally referred to as typical and atypical flutter can be considered as electrophysiologically different entities. This element might influence the different actions of drugs on AFI “tout-court”.

Keywords

Atrial Fibrillation Sinus Rhythm Atrial Flutter Underlying Heart Disease Acute Termination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cheng J, Cabeen WR, Scheinman MM (1998) Mechanism and anatomic substrates of atypical atrial flutter in the right atrium. Pacing Clin Electrophysiol 21:795 (abstr)Google Scholar
  2. 2.
    Jais P, Haïssanguerre M, Shah DC et al (1998) A new electrophysiological substrate for spontaneous left atrial flutter (abstract). Pacing Clin Electrophysiol 21:794Google Scholar
  3. 3.
    Inoue H, Yamashita T, Nozaki A, Sugimoto T (1999) Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol 18:1089–1104Google Scholar
  4. 4.
    Murdock CJ, Kyles AF, Yeung-Lai-Wah JA et al (1990) Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 66:755–757PubMedCrossRefGoogle Scholar
  5. 5.
    Tunick PA, Mc Elhinney L, Mitchell T, Kronzon J (1992) The alternation between atrial flutter and atrial fibrillation. Chest 101:34–36PubMedCrossRefGoogle Scholar
  6. 6.
    Bianconi L, Boccadamo R, Pappalardo A et al (1989) Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 64:335–338PubMedCrossRefGoogle Scholar
  7. 7.
    Suttorp M J, Kingma JH, Jessuron ER et al (1990) The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 16:1722–1727PubMedCrossRefGoogle Scholar
  8. 8.
    Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG (1989) Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 63:693–696PubMedCrossRefGoogle Scholar
  9. 9.
    Goy JJ, Hurni M, Maendly R et al (1985) Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 6:518–524PubMedGoogle Scholar
  10. 10.
    Murray KT (1998) Ibutilide. Circulation 97:493–497CrossRefGoogle Scholar
  11. 11.
    Foster RH, Wilde MI, Markhan A (1997) Ibutilide. A review of its pharmacological properties and clinical in the acute management of atrial flutter and fibrillation. Drugs 54:1–17CrossRefGoogle Scholar
  12. 12.
    Stambler BS, Wood MA, Ellenbogen KA et al (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94:1613–1621PubMedCrossRefGoogle Scholar
  13. 13.
    Ellenbogen KA, Stambler BS, Wood MA et al (1996) Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28:130–136PubMedCrossRefGoogle Scholar
  14. 14.
    Volgman AS, Stambler BS, Kappagoda C et al (1996) Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter (abstract). Pacing Clin Electrophysiol 19:169Google Scholar
  15. 15.
    Vos MA, Golitsyn SR, Stangl K et al (1998) Superiority of Ibutilide (a new class III agent) over dl-sotalol in converting atrial flutter and atrial fibrillation. Heart 79:568–575PubMedGoogle Scholar
  16. 16.
    Glatter K, Yang Y, Chatterjee K et al (2001) Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 103:253–257PubMedCrossRefGoogle Scholar
  17. 17.
    Stambler BS, Wood MA, Ellenbogen KA (1996) Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 77:960–966PubMedCrossRefGoogle Scholar
  18. 18.
    Mounsey JP, Di Marco JP (2000) Dofetilide. Circulation 102:2665–2670CrossRefGoogle Scholar
  19. 19.
    Suttorp MJ, Polak P, Van’t Hof A et al (1992) Efficacy and safety of a new selective class III antiarrythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 69:417–419PubMedCrossRefGoogle Scholar
  20. 20.
    Falk RH, Pollak A, Singh SN, Friedrich T (1997) Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 29:385–390PubMedCrossRefGoogle Scholar
  21. 21.
    Norgaard BL, Wachtell K, Christensen PD et al (1999) Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J 137:1062–1069PubMedCrossRefGoogle Scholar
  22. 22.
    Crijns HJG, Van Gelder IC, Kingma JH et al (1994) Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class I C drug. Eur Heart J 15:1403–1408PubMedCrossRefGoogle Scholar
  23. 23.
    Bianconi L, Castro A, Dinelli M et al (2000) Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. Eur Heart J 21:1265–1273PubMedCrossRefGoogle Scholar
  24. 24.
    Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102:2385–2390PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2002

Authors and Affiliations

  • N. Baldi
    • 1
  • V. A. Russo
    • 1
  • V. Morrone
    • 1
  • L. Di Gregorio
    • 1
  • L. Liconso
    • 1
  • G. Polimeni
    • 1
  1. 1.Cardiovascular DepartmentAzienda Ospedaliera S.SAnnunziataTarantoItaly

Personalised recommendations